The March 26 issue of "The Tan Sheet" offers a front-row view of last week's FDA public hearing on the proposed "new paradigm" for nonprescription drug access.
We've got in-depth coverage and analysis of what agency officials think is needed to expand the possibilities for OTC switch, as well as what major industry players like GlaxoSmithKline could bring to the table.
This week's edition also looks at Procter & Gamble's "New Chapter" in consumer health products, what OTC firms should know about social media and why adolescent consumers have such a hard time obtaining emergency contraception.
For much more, and "The Tan Sheet's" March 26 table of contents, click here.
"The Tan Sheet" is your source for the most comprehensive and in-depth coverage of the OTC drug and nutritional industries. Start your free trial subscription here -- no credit card required.
Your company or organization may already provide access to "The Tan Sheet." To find out if you should have access, email custcare@elsevier.com.
Also, follow "The Tan Sheet" on Twitter and Facebook.
--Dan Schiff (d.schiff@elsevier.com)
